黄芪甲苷对高位脊髓损伤大鼠急性期心肌损伤的影响  

Effects of astragaloside IV on acute myocardial injury in rats with high‑level spinal cord injury

作　　者：黄钦凤 郑颖[2] 魏丽钦 廖烨 李佳琦 林丽君 陈嘉欣 郑如洁 林文娜 陈辉[1] Huang Qinfeng;Zheng Ying;Wei Liqin;Liao Ye;Li Jiaqi;Lin Lijun;Chen Jiaxin;Zheng Rujie;Lin Wenna;Chen Hui(Department of Anesthesiology,the First Affiliated Hospital of Fujian Medical University,Anesthesiology Institute of Fujian Medical University,Department of Anesthesiology,National Regional Medical Center,Binhai Campus of the First Affiliated Hospital of Fujian Medical University,Fuzhou 350005,China;Department of Anesthesiology,People′s Hospital Affiliated to Fujian University of Traditional Chinese Medicine,Fuzhou 350004,China;Department of Anesthesiology,Fujian Medical University Union Hospital,Fuzhou 350001,China)

机构地区：[1]福建医科大学附属第一医院麻醉科,福建医科大学麻醉学研究所,福建医科大学附属第一医院滨海院区国家区域医疗中心麻醉科,福州350005 [2]福建中医药大学附属人民医院麻醉科,福州350004 [3]福建医科大学附属协和医院麻醉科,福州350001

出　　处：《中华创伤杂志》2024年第11期1028-1039,共12页Chinese Journal of Trauma

基　　金：福建医科大学启航基金(2023QH1066)。

摘　　要：目的探讨黄芪甲苷(AS-Ⅳ)对高位脊髓损伤(SCI)大鼠急性期心肌损伤的影响。方法选取24只8~10周龄、体重250~300 g的健康雄性SD大鼠,按随机数字表法分为四组:假手术组、高位SCI组(SCI组)、高位SCI+AS-Ⅳ组(SCI+AS-Ⅳ组)和高位SCI+AS-Ⅳ+沉默信息调节因子1(SIRT1)抑制剂EX527组(SCI+AS-Ⅳ+EX527组),每组6只。采用改良Allen法建立SCI模型,假手术组仅暴露脊髓。SCI+AS-Ⅳ组在伤后即刻腹腔注射40 mg/kg AS-Ⅳ;SCI+AS-Ⅳ+EX527组于伤前1 h腹腔注射5 mg/kg EX527,并在伤后即刻腹腔注射40 mg/kg AS-Ⅳ;假手术组和SCI组腹腔注射等量生理盐水。伤后苏醒即刻观察并记录各组大鼠的后肢运动功能,并采用BBB法评估。伤后24 h,透射电镜下观察心肌细胞超微结构;ELISA法检测血清肌钙蛋白I(cTnI)、心肌组织炎症因子白细胞介素(IL)-18和IL-1β水平;二氢乙啶(DHE)法检测心肌组织活性氧(ROS)水平;生化法检测超氧化物歧化酶(SOD)活性和丙二醛(MDA)水平;RT-PCR和Western blot检测核苷酸结合寡聚化结构域样受体3(NLRP3)、含半胱氨酸的天冬氨酸蛋白水解酶-1(caspase-1)、消皮素D(GSDMD)、SIRT1和过氧化物酶体增殖物激活受体γ共激活因子-1α(PGC-1α)mRNA及蛋白表达水平;caspase-1和TUNEL免疫荧光双染色法检测心肌细胞焦亡率。结果伤后苏醒即刻,假手术组后肢活动正常,BBB评分均为21(21,21)分;其余各组双后肢呈弛缓性瘫痪,自主排泄消失,BBB评分均为0(0,0)分。伤后24 h透射电镜显示,假手术组心肌细胞超微结构未见明显异常,SCI组细胞出现不同程度改变。伤后24 h ELISA法检测结果显示,SCI组血清cTnI水平为(1435.3±148.1)pg/ml,高于假手术组的(619.6±95.4)pg/ml(P<0.01);SCI+AS-Ⅳ组cTnI水平为(1154.0±80.0)pg/ml,低于SCI组(P<0.01);SCI+AS-Ⅳ+EX527组cTnI水平为(1321.8±50.2)pg/ml,高于SCI+AS-Ⅳ组(P<0.05)。SCI组心肌组织IL-18和IL-1β水平分别为(493.0±145.0)pg/ml、(936.7±93.2)pg/ml,均高于假�Objective To investigate the effects of astragaloside IV(AS‑IV)on acute myocardial injury in rats with high‑level spinal cord injury(SCI).Methods Twenty‑four healthy male SD rats,aged 8‑10 weeks with a body weight of 250‑300 g,were randomly divided into 4 groups using a random number table method:sham operation group,high‑level SCI group(SCI group),high‑level SCI+AS‑IV group(SCI+AS‑IV group)and high‑level SCI+AS‑IV+silent information regulator 1(SIRT1)inhibitor EX527 group(SCI+AS‑IV+EX527 group),with 6 rats in each group.The SCI model was established using the modified Allen method and the sham operation group underwent the spinal cord exposure only.In the SCI+AS‑IV group,40 mg/kg of AS‑IV was injected intraperitoneally immediately after injury.SCI+AS‑IV+EX527 group received an intraperitoneal injection of 5 mg/kg EX527 at one hour before injury and another injection of 40 mg/kg AS‑IV in the same way immediately after injury.The sham operation group and the SCI group received an equal volume of saline via intraperitoneal injection.Immediately after awakening from injury,the hind limb motor function of the rats in each group was observed,recorded and then evaluated using the BBB method.At 24 hours after injury,the ultrastructure of the cardiomyocytes was examined under a transmission electron microscope;the levels of serum cardiac troponin I(cTnI),myocardial tissue inflammatory factors interleukin(IL)‑18 and IL‑1βwere quantified by the ELISA method;the level of reactive oxygen species(ROS)of the myocardial tissue was assessed utilizing the dihydroethidium(DHE)assay;biochemical analyses were employed to determine the superoxide dismutase(SOD)activity and malondialdehyde(MDA)concentrations;mRNA and protein expression levels of nucleotide‑binding oligomerization domain‑like receptor protein 3(NLRP3),cysteinyl aspartate specific proteinase‑1(caspase‑1),gasdermin D(GSDMD),SIRT1 and peroxisome proliferator‑activated receptorγcoactivator‑1α(PGC‑1α)were examined using

关 键 词：脊髓损伤 心肌 黄芪甲苷 

分 类 号：R285.5[医药卫生—中药学]